Health related quality of life and social and demographic informations
OtherAt the inclusion visit with a self-assessment questionnaire
NCT Number: NCT02592174
The primary objective is to measure the prevalence of according to the Frascati classification in a HIV-infected population aged between 55 and 70 years (exposed group) and to compare it with the prevalence of HIV-Associated Neurocognitive Disorders (HAND) in unexposed subjects from the general population-based cohort CONSTANCES, matching subjects on age, gender, geographical origin and socioprofessional category.
Looking for future studies?
Notify Me55 year–70 year
All sexes
Interventional
Not applicable
Centre Hospitalier de Cannes - Service de Médecine Interne Oncologie, Cannes, France
Secondary objectives are:
Methodology:
HIV-infected subjects aged between 55 and 70 years will be recruited in centres that support people who living with HIV usually. The study will be proposed consecutively to all subjects aged between 55 and 70 year. A brief inquiry will collect motives on subjects that refuse to participate. A minimum of 70 subjects by 5 years age categories will be included. Unexposed subjects will be recruited in the same regions as their HIV-infected counterparts from the CONSTANCES database, a general population health cohort, after random selection matched on age, gender, geographical origin and socioprofessional category (2 HIV-unexposed subjects for 1 exposed subject). Data collection will follow the same methods as in the CONSTANCES cohort, in particular the neurocognitive tests by trained neuropsychologists.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
For the HIV-infected, inclusion criteria are:
Non-inclusion criteria are:
Inclusion criteria
for the subjects from the CONSTANCES cohort are an age between 55 and 70 years. Non-inclusion criteria are the same as the HIV-infected subjects, as well as reported HIV-infection or antiretroviral treatment.
At the inclusion visit with a self-assessment questionnaire
At the neurocognitive visit, with standard test as CONSTANCES cohort
Standard magnetic resonance imaging
Time frame: at month 3 (neurocognitive evaluation)
Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at month 3 (the neurocognitive visit).
Time frame: at month 3 (neurocognitive evaluation)
Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at month 3 (the neurocognitive visit).
Time frame: at month 3 (neurocognitive evaluation)
Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at month 3 (the neurocognitive visit).
Time frame: at month 3 (neurocognitive evaluation)
Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at month 3 (the neurocognitive visit).
Time frame: at month 3 (neurocognitive evaluation)
Time frame: at month 3 (neurocognitive evaluation)
Time frame: at month 3 (neurocognitive evaluation)
ANRS, Emerging Infectious Diseases
Other Gov
Acronym: HAND55-70
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04233879
HIV-1 Infection
Birmingham, Alabama, United States
View Trial DetailsNCT02906137
HIV-1 Infection
Toulouse, France
View Trial DetailsNCT01453192
Chronic Disease, Chronic Renal Insufficiency
Bordeaux, France
View Trial DetailsNCT04133012
HIV-1 Infection
Clamart, France
View Trial Details